These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 28283584)

  • 1. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
    Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
    Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways.
    Cuppens T; Moisse M; Depreeuw J; Annibali D; Colas E; Gil-Moreno A; Huvila J; Carpén O; Zikán M; Matias-Guiu X; Moerman P; Croce S; Lambrechts D; Amant F
    Int J Cancer; 2018 Mar; 142(6):1230-1243. PubMed ID: 29063609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
    Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
    Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
    Lin DI; Hemmerich A; Edgerly C; Duncan D; Severson EA; Huang RSP; Ramkissoon SH; Connor YD; Shea M; Hecht JL; Ali SM; Vergilio JA; Ross JS; Elvin JA
    Gynecol Oncol; 2020 May; 157(2):357-366. PubMed ID: 32156473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options.
    Gay LM; Kim S; Fedorchak K; Kundranda M; Odia Y; Nangia C; Battiste J; Colon-Otero G; Powell S; Russell J; Elvin JA; Vergilio JA; Suh J; Ali SM; Stephens PJ; Miller VA; Ross JS
    Oncologist; 2017 Jul; 22(7):834-842. PubMed ID: 28495808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
    Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
    J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Seligson ND; Kautto EA; Passen EN; Stets C; Toland AE; Millis SZ; Meyer CF; Hays JL; Chen JL
    Oncologist; 2019 Jul; 24(7):973-979. PubMed ID: 30541756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
    Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
    J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated mutational landscape analysis of uterine leiomyosarcomas.
    Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment.
    An Y; Wang S; Li S; Zhang L; Wang D; Wang H; Zhu S; Zhu W; Li Y; Chen W; Ji S; Guo X
    BMC Cancer; 2017 Sep; 17(1):639. PubMed ID: 28893210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
    Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
    Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
    Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
    Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
    Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
    McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
    Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
    Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
    Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
    Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
    Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
    Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
    Oncologist; 2024 Jul; 29(7):560-565. PubMed ID: 38716772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative immunohistochemical and molecular analysis of uterine and extrauterine leiomyosarcomas.
    Rao UN; Finkelstein SD; Jones MW
    Mod Pathol; 1999 Nov; 12(11):1001-9. PubMed ID: 10574596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
    Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
    Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.